New York, New York–(Newsfile Corp. – January 20, 2021) – Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. (“Neoleukin” or the “Company”) (NASDAQ: NLTX). Su ch investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Neoleukin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On January 8, 2021, Neoleukin announced that “on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.” Neoleukin disclosed that “[t]he FDA has informed Neoleukin that it needs to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201” and that “[t]he FDA also had additional requests not related to the clinical hold to be addressed by amendment of the IND.”
On this news, Neoleukin’s stock price fell $1.73 per share, or 10.96%, to close at $14.05 per share on January 8, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72506